Pharmacodynamics of Adjunctive Vorapaxar With DAPT in Type 2 Diabetes
Endocrinology Advisor,
Researchers categorized patients with prior myocardial infarction or peripheral arterial disease who were also receiving dual…
Researchers categorized patients with prior myocardial infarction or peripheral arterial disease who were also receiving dual…
Platelet-mediated thrombogenicity is reduced when vorapaxar is added to dual antiplatelet therapy (DAPT) without affecting clot…
Dominick J. Angiolillo PARIS — When added to dual antiplatelet therapy, vorapaxar reduced platelet-mediated thrombogenicity…